Profund Advisors LLC Acquires 9,582 Shares of BioMarin Pharmaceutical Inc. $BMRN

Profund Advisors LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 34.3% during the third quarter, Holdings Channel reports. The firm owned 37,548 shares of the biotechnology company’s stock after acquiring an additional 9,582 shares during the quarter. Profund Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $2,253,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Vise Technologies Inc. grew its position in shares of BioMarin Pharmaceutical by 125.1% during the 3rd quarter. Vise Technologies Inc. now owns 12,096 shares of the biotechnology company’s stock valued at $726,000 after buying an additional 6,722 shares during the last quarter. Grandfield & Dodd LLC lifted its holdings in BioMarin Pharmaceutical by 3.4% in the third quarter. Grandfield & Dodd LLC now owns 18,872 shares of the biotechnology company’s stock worth $1,132,000 after acquiring an additional 629 shares during the last quarter. Choreo LLC lifted its holdings in BioMarin Pharmaceutical by 9.5% in the third quarter. Choreo LLC now owns 11,930 shares of the biotechnology company’s stock worth $716,000 after acquiring an additional 1,033 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in BioMarin Pharmaceutical by 14.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 35,320 shares of the biotechnology company’s stock worth $2,115,000 after acquiring an additional 4,559 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its stake in BioMarin Pharmaceutical by 9.6% in the third quarter. D.A. Davidson & CO. now owns 47,798 shares of the biotechnology company’s stock valued at $2,868,000 after acquiring an additional 4,197 shares during the period. 98.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BMRN has been the subject of several recent research reports. HC Wainwright reaffirmed a “neutral” rating and set a $60.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, September 10th. UBS Group assumed coverage on BioMarin Pharmaceutical in a report on Thursday, October 15th. They issued a “buy” rating and a $88.00 price target on the stock. Canaccord Genuity Group boosted their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Cantor Fitzgerald restated an “overweight” rating and set a $86.00 price objective on shares of BioMarin Pharmaceutical in a research note on Tuesday, October 20th. Finally, Weiss Ratings downgraded BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 18th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $88.38.

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $58.51 on Monday. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average price of $60.62 and a two-hundred day moving average price of $58.44. The firm has a market capitalization of $11.33 billion, a price-to-earnings ratio of 158.14, a PEG ratio of 0.64 and a beta of 0.21. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $70.98.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $989.71 million during the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the prior year, the firm earned $1.44 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 2.59 earnings per share for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.